Becker's Healthcare August 27, 2024
Elizabeth Gregerson

GLP-1s reduced mortality and complications from cardiovascular events, according to a study published Aug. 22 in Diabetes, Obesity and Metabolism: A Journal of Pharmacology and Therapeutics.

Researchers from Taiwan analyzed data from more than 3 million patients with obesity in the TriNetX Global Network between Jan. 1, 2016 and March 31, 2024. Of those patients, 12,123 individuals who received GLP-1 medication were matched with the same number of individuals who had not received it.

Patients who received the medication had a significantly lower risk of mortality, ischemic heart disease, heart failure, arrhythmias,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Clinical Trials, Patient / Consumer, Pharma / Biotech, Provider, Trends
Related Articles:
How Life Sciences Can Drive Innovation And Sustainability In Returns Management
How Americans feel about weight-loss drugs, in 3 charts
Tariffs on China threaten could drive up drug costs, exacerbate shortages: 5 notes
Drugmakers prep for bird flu outbreak, despite continued low risk
Heart health differences in men and women: Tiny RNA molecules play key role, study finds

Share This Article